时间限制的饮食改善了间歇性低氧诱导的低血糖症
Chloe P Afif1, Katherine P Brewster2, Michelle P Zhang3
1University of California Santa Barbara, Santa Barbara, CA, USA.
Sleep
|November 25, 2025
概括
时间限制饮食 (TRE) 缓解间歇性缺氧 (IH) 引起的葡萄糖失调,这是阻塞性睡眠呼吸暂停 (OSA) 的模型. TRE改善胰岛素分泌,可能是治疗OSA的新治疗策略.
科学领域:
- 代谢生理学 代谢生理学
- 睡眠医学 睡眠医学
- 内分泌学 在内分泌学.
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 与异常的葡萄糖代谢有关.
- 慢性间歇性缺氧 (IH),模仿OSA,诱导类似的代谢障碍.
- 时间限制饮食 (TRE) 显示了代谢益处,但其对肥胖症中IH诱导的失糖症的影响尚不清楚.
研究的目的:
- 调查TRE在改善IG暴露的OSA肥胖动物模型中的葡萄糖恒温的疗效.
- 为了确定TRE是否可以抵消IH诱导的失糖症和相关的代谢变化.
主要方法:
- 在高脂肪饮食中肥胖的C57BL/6J小鼠被暴露在间歇性空气 (IA) 或IH中四周.
- 小鼠被分配给任意食或TRE (9小时/天摄入量).
- 在暴露期间之前和之后进行了葡萄糖耐受性测试 (GTT).
主要成果:
- 与对照组相比,TRE在IH组显著降低了禁食葡萄糖.
- 在IA和IH ad libitum组中,TRE阻止了在曲线下葡萄糖耐受性测试面积的增加.
- 在IH小鼠中,TRE使血清益胰岛素和益胰岛素对胰岛素的比率升高正常化,胰腺基因表达发生了有利的变化.
结论:
- TRE有效地减轻了IH对葡萄糖平衡的不良影响,主要是通过改善胰腺胰岛素分泌.
- 在IH条件下,TRE对葡萄糖调节的益处在IH条件下得到增强.
- 在OSA中,TRE为管理代谢功能障碍提供了潜在的治疗方法.
相关概念视频
Hypoglycemia and Glucagon
779
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
779
Metabolic States of the Body: The Postabsorptive State
1.2K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.2K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Metabolic States of the Body: Fasting and Starvation
2.7K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
2.7K
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573


